HeartBeam, Inc. (BEAT)

Significant stock events for HeartBeam, Inc. in the past six months include the demonstration of high accuracy rates for arrhythmia detection algorithms in September 2025. In November 2025, the company reported its Third Quarter results, noting a decrease in net cash used in operating activities and Roth Capital initiated coverage with a 'Buy' rating. December 2025 saw a surge in stock price following FDA clearance for its 12-lead ECG synthesis software, with H.C. Wainwright raising the price target. In January 2026, Bryan Humbarger was appointed as Chief Commercial Officer. As of February 2026, the closing stock price was $1.29, with the company operating at a loss and experiencing high volatility.

The provided information does not explicitly detail demand seasonality for HeartBeam, Inc.'s products and services. The demand for its products is likely driven by the prevalence of cardiac diseases and the growing need for remote cardiac diagnostics and monitoring, rather than seasonal fluctuations.

HeartBeam, Inc. is a medical technology company focused on transforming cardiac care through advanced ECG solutions for remote patient monitoring. The company develops and commercializes ambulatory ECG solutions for detecting and monitoring cardiac disease outside of traditional healthcare facilities. HeartBeam's key product is a credit card-sized, cable-free ECG device utilizing its patented VECG technology, which has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis.

HeartBeam, Inc. is headquartered in Santa Clara, California, and is primarily focused on the U.S. market, particularly in obtaining FDA clearances for its telehealth products.

HeartBeam, Inc. has received positive recognition for its innovative technology, including the 2025 Innovation Award in Remote Cardiac Diagnostics and recognition as a global IP and technology leader in portable cardiac diagnostics. The company also received the 'Rising Star' award at the 6th Annual Digital Health Hub Foundation Awards.

HeartBeam, Inc. has 47 institutional owners and shareholders holding 3,795,739 shares. Major institutional shareholders include Vanguard Group Inc., VTSMX, VEXMX, UBS Group AG, Smith, Salley & Associates, Geode Capital Management, Llc, Ritholtz Wealth Management, Kestra Private Wealth Services, Llc, O'shaughnessy Asset Management, Llc, and Stifel Financial Corp. Individual major shareholders include Mark Strome, Andrew Schwartzberg, Branislav Vajdic, and Willem Elfrink. Individuals hold 19.7% of the shares, while institutional ownership stands at approximately 11.16% to 12.0%.